Deutsche Bank Reiterates CHF 264 Price Target for Roche (ROG)
Roche (VTX:ROG) received a CHF 264 price target from equities researchers at Deutsche Bank in a research report issued to clients and investors on Tuesday. The firm currently has a “neutral” rating on the healthcare company’s stock. Deutsche Bank’s price target suggests a potential upside of 9.77% from the company’s current price.
Other research analysts also recently issued reports about the company. Jefferies Group set a CHF 290 target price on Roche and gave the stock a “buy” rating in a report on Thursday, September 21st. Goldman Sachs Group set a CHF 325 price objective on Roche and gave the company a “buy” rating in a research note on Thursday, September 21st. Barclays set a CHF 295 price objective on Roche and gave the company a “buy” rating in a research note on Wednesday, September 13th. J P Morgan Chase & Co reissued a “buy” rating on shares of Roche in a research note on Monday, September 11th. Finally, Credit Suisse Group set a CHF 300 price objective on Roche and gave the company a “buy” rating in a research note on Monday, September 11th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of CHF 261.84.
Shares of Roche (ROG) traded down CHF 0.10 on Tuesday, reaching CHF 240.50. The company’s stock had a trading volume of 853,694 shares, compared to its average volume of 1,680,000. Roche has a 52-week low of CHF 220.50 and a 52-week high of CHF 273.
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Holding Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holding Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.